Radioprotective effect of olanzapine as an anti-psychotic drug against genotoxicity and apoptosis induced by ionizing radiation on human lymphocytes

  • Mohammad Asghari
  • Zahra Shaghaghi
  • Soghra Farzipour
  • Arash Ghasemi
  • Seyed Jalal HosseinimehrEmail author
Original Article


Olanzapine (OLA), is prescribed as an anti-psychotic medicine in schizophrenia patients. In this study, the protective effect of OLA against genotoxicity and apoptosis induced by ionizing radiation in human healthy lymphocytes was evaluated. At first, the antioxidant activities of OLA were assayed by two different methods as free radical scavenging with DPPH (2,2-diphenyl-1-picryl-hydrazyl) and ferric reducing power methods. In in vitro experiment, human blood samples were treated with OLA at various concentrations (0.25–20 μM) for 3 h and then were exposed to X-ray at a dose of 150 cGy. The genotoxicity was assessed in binucleated human lymphocytes with micronuclei assay. The apoptotic lymphocytes were assessed by flow cytometry in OLA treated and/or irradiated lymphocytes. OLA exhibited free radical scavenging and reducing power activities more than ascorbic acid. The results showed that the lymphocytes treated with OLA and later exposed to IR presented lower frequencies of micronuclei and apoptosis compared to the control sample which was irradiated and not treated to OLA. The maximum radioprotection was observed at 20 μM of OLA with 83% of efficacy. The present study suggested the protective role for OLA in protection radiation-induced genetic damage and apoptosis induced by ionizing irradiation in human normal cells.


Olanzapine Ionizing radiation Genotoxicity Radioprotective Apoptosis 



Funding was provided by Elite Researcher Grant Committee from the National Institute for Medical Research Development, Grant No. 963296, Tehran, Iran.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by research and ethical committees of the Iranian National Institute for Medical Research and Development (ID#IR.NIMAD.REC.1396. 235).

Informed consent

Written informed consents were also obtained from healthy male volunteers. This study was performed only in vitro experiments on blood samples of healthy male volunteers.


  1. 1.
    Hosseinimehr SJ (2010) Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today 15(21):907–918CrossRefGoogle Scholar
  2. 2.
    Hosseinimehr SJ (2007) Trends in the development of radioprotective agents. Drug Discov Today 12(19–20):794–805. CrossRefGoogle Scholar
  3. 3.
    Hosseinimehr SJ, Ahmadi A, Beiki D, Habibi E, Mahmoudzadeh A (2009) Protective effects of hesperidin against genotoxicity induced by (99 m)Tc-MIBI in human cultured lymphocyte cells. Nucl Med Biol 36(7):863–867. CrossRefGoogle Scholar
  4. 4.
    Hosseinimehr SJ, Mahmoudzadeh A, Ahmadi A, Mohamadifar S, Akhlaghpoor S (2009) Radioprotective effects of hesperidin against genotoxicity induced by gamma-irradiation in human lymphocytes. Mutagenesis 24(3):233–235. CrossRefGoogle Scholar
  5. 5.
    Hosseinimehr SJ, Nobakht R, Ghasemi A, Pourfallah TA (2015) Radioprotective effect of mefenamic acid against radiation-induced genotoxicity in human lymphocytes. Radiat Oncol J 33(3):256–260. CrossRefGoogle Scholar
  6. 6.
    Alizadeh F, Asghari M, Torabizadeh SA, Rahmanian N, Ghasemi A, Hosseinimehr SJ (2018) Radioprotective effect of sinapic acid against genotoxicity and apoptosis induced by ionizing radiation on human lymphocytes. Lett Drug Des Discov 15(11):1147–1154. CrossRefGoogle Scholar
  7. 7.
    Zal Z, Ghasemi A, Azizi S, Asgarian-Omran H, Montazeri A, Hosseinimehr SJ (2018) Radioprotective effect of cerium oxide nanoparticles against genotoxicity induced by ionizing radiation on human lymphocytes. Curr Radiopharm 11(2):109–115. CrossRefGoogle Scholar
  8. 8.
    Werner FM, Covenas R (2014) Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf 13(8):1031–1042. CrossRefGoogle Scholar
  9. 9.
    Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14(4):141–147. CrossRefGoogle Scholar
  10. 10.
    Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B (2018) Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev 9:CD012555. Google Scholar
  11. 11.
    Csernansky JG, Martin MV, Czeisler B, Meltzer MA, Ali Z, Dong H (2006) Neuroprotective effects of olanzapine in a rat model of neurodevelopmental injury. Pharmacol Biochem Behav 83(2):208–213. CrossRefGoogle Scholar
  12. 12.
    Stanisavljevic A, Peric I, Pantelic M, Filipovic DM (2017) Olanzapine alleviates oxidative stress in the liver of socially isolated rats. Can J Physiol Pharmacol 95(6):634–640. CrossRefGoogle Scholar
  13. 13.
    Wang H, Xu H, Dyck LE, Li XM (2005) Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 81(4):572–580. CrossRefGoogle Scholar
  14. 14.
    Brinholi FF, Farias CC, Bonifacio KL, Higachi L, Casagrande R, Moreira EG, Barbosa DS (2016) Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models. Biomed Pharmacother 81:411–415. CrossRefGoogle Scholar
  15. 15.
    Sadowska-Bartosz I, Galiniak S, Bartosz G, Zuberek M, Grzelak A, Dietrich-Muszalska A (2016) Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia. Schizophr Res 176(2–3):245–251. CrossRefGoogle Scholar
  16. 16.
    Al-Chalabi BM, Thanoon IA, Ahmed FA (2009) Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 59(1):8–11. CrossRefGoogle Scholar
  17. 17.
    Hosseinimehr SJ, Azadbakht M, Mousavi SM, Mahmoudzadeh A, Akhlaghpoor S (2007) Radioprotective effects of hawthorn fruit extract against gamma irradiation in mouse bone marrow cells. J Radiat Res (Tokyo) 48(1):63–68. CrossRefGoogle Scholar
  18. 18.
    Hosseinimehr SJ, Izakmehri M, Ghasemi A (2015) In vitro protective effect of atorvastatin against ionizing radiation induced genotoxicity in human lymphocytes. Cell Mol Biol (Noisy-le-grand) 61(1):68–71Google Scholar
  19. 19.
    Hosseinimehr SJ, Fathi M, Ghasemi A, Shiadeh SN, Pourfallah TA (2017) Celecoxib mitigates genotoxicity induced by ionizing radiation in human blood lymphocytes. Res Pharm Sci 12(1):82–87. CrossRefGoogle Scholar
  20. 20.
    Cheki M, Shirazi A, Mahmoudzadeh A, Bazzaz JT, Hosseinimehr SJ (2016) The radioprotective effect of metformin against cytotoxicity and genotoxicity induced by ionizing radiation in cultured human blood lymphocytes. Mutat Res 809:24–32. CrossRefGoogle Scholar
  21. 21.
    Fenech M (2000) The in vitro micronucleus technique. Mutat Res 455(1–2):81–95. CrossRefGoogle Scholar
  22. 22.
    Macwan CP, Patel MA (2010) Antioxidant potential of dried root of Capparis zylanica linn. Int J Pharm Pharm Sci 30:58–60Google Scholar
  23. 23.
    Pinkawa M, Brzozowska K, Kriehuber R, Eble MJ, Schmitz S (2016) Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients. Future Oncol 12(5):617–624. CrossRefGoogle Scholar
  24. 24.
    Sharma D, Sandur SK, Rashmi R, Maurya DK, Suryavanshi S, Checker R, Krishnan S, Sainis KB (2010) Differential activation of NF-kappaB and nitric oxide in lymphocytes regulates in vitro and in vivo radiosensitivity. Mutat Res 703(2):149–157. CrossRefGoogle Scholar
  25. 25.
    Weiss JF, Landauer MR (2000) Radioprotection by antioxidants. Ann N Y Acad Sci 899:44–60CrossRefGoogle Scholar
  26. 26.
    Castillo J, Benavente-Garcia O, Lorente J, Alcaraz M, Redondo A, Ortuno A, Del Rio JA (2000) Antioxidant activity and radioprotective effects against chromosomal damage induced in vivo by X-rays of flavan-3-ols (Procyanidins) from grape seeds (Vitis vinifera): comparative study versus other phenolic and organic compounds. J Agric Food Chem 48(5):1738–1745. CrossRefGoogle Scholar
  27. 27.
    Farias CCd, Bonifácio KL, Matsumoto AK, Higachi L, Casagrande R, Moreira EG, Barbosa DS (2014) Comparison of the antioxidant potential of antiparkinsonian drugs in different in vitro models. Braz J Pharm Sci 50:819–826CrossRefGoogle Scholar
  28. 28.
    Zhao QL, Ito H, Kondo T, Uehara T, Ikeda M, Abe H, Saitoh JI, Noguchi K, Suzuki M, Kurachi M (2019) Antipsychotic drugs scavenge radiation-induced hydroxyl radicals and intracellular ROS formation, and protect apoptosis in human lymphoma U937 cells. Free Radic Res. Google Scholar
  29. 29.
    Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, Lee S, Liu C, Elmquist JK (2017) The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest 127(9):3402–3406. CrossRefGoogle Scholar
  30. 30.
    Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123(2–3):225–233. CrossRefGoogle Scholar
  31. 31.
    Townsend LK, Peppler WT, Bush ND, Wright DC (2018) Obesity exacerbates the acute metabolic side effects of olanzapine. Psychoneuroendocrinology 88:121–128. CrossRefGoogle Scholar
  32. 32.
    Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C (2017) The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry 17(1):373. CrossRefGoogle Scholar
  33. 33.
    Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L’Italien G (2009) The incidence of diabetes in atypical antipsychotic users differs according to agent–results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18(9):791–799. CrossRefGoogle Scholar
  34. 34.
    Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T (2017) Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40(9):771–781. CrossRefGoogle Scholar
  35. 35.
    Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B, Mamikonyan E, Kales HC (2016) Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 73(5):535–541. CrossRefGoogle Scholar
  36. 36.
    Yuan M, Sperry L, Malhado-Chang N, Duffy A, Wheelock V, Farias S, O’Connor K, Olichney J, Shahlaie K, Zhang L (2017) Atypical antipsychotic therapy in Parkinson’s disease psychosis: a retrospective study. Brain Behav 7(6):e00639. CrossRefGoogle Scholar
  37. 37.
    Marras C, Herrmann N, Anderson GM, Fischer HD, Wang X, Rochon PA (2012) Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex. Am J Geriatr Pharmacother 10(6):381–389. CrossRefGoogle Scholar
  38. 38.
    Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24(5):2381–2392. CrossRefGoogle Scholar
  39. 39.
    Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y (2017) Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol 83(7):1369–1379. CrossRefGoogle Scholar
  40. 40.
    Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A, Cerveri G, Baldi ML, Barale F (2005) Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 20(1):55–60. CrossRefGoogle Scholar
  41. 41.
    Kelly DL, Richardson CM, Yu Y, Conley RR (2006) Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol 21(6):393–398. CrossRefGoogle Scholar
  42. 42.
    Bergemann N, Frick A, Parzer P, Kopitz J (2004) Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 37(2):63–68. CrossRefGoogle Scholar
  43. 43.
    Eriksson D, Stigbrand T (2010) Radiation-induced cell death mechanisms. Tumour Biol 31(4):363–372. CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Radiopharmacy, Faculty of PharmacyMazandaran University of Medical SciencesSariIran
  2. 2.Student Research CommitteeMazandaran University of Medical SciencesSariIran
  3. 3.Department of Nuclear Medicine and Molecular Imaging, Clinical Development Research Unit of Farshchian Heart CenterHamadan University of Medical SciencesHamadanIran
  4. 4.Department of Radiology and Radiation Oncology, Faculty of MedicineMazandaran University of Medical SciencesSariIran

Personalised recommendations